{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:32:18Z","timestamp":1783132338981,"version":"3.54.6"},"reference-count":99,"publisher":"Elsevier","isbn-type":[{"value":"9780128231210","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer&apos;s Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT03801642"],"award-info":[{"award-number":["NCT03801642"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.irn.2020.03.018","type":"book-chapter","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T08:11:32Z","timestamp":1597133492000},"page":"113-140","source":"Crossref","is-referenced-by-count":45,"title":["A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?"],"prefix":"10.1016","member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2020.03.018_bb0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","author":"Alzheimer's Association","year":"2019","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.018_bb0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jalz.2017.09.011","article-title":"Evidence for brain glucose dysregulation in Alzheimer's disease","volume":"14","author":"An","year":"2018","journal-title":"Alzheimer's & Dementia"},{"key":"10.1016\/bs.irn.2020.03.018_bb0020","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/dom.13761","article-title":"Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial","volume":"21","author":"Anholm","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/bs.irn.2020.03.018_bb0025","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/bs.irn.2020.03.018_bb0030","series-title":"Leptin. Endocrine updates","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-31416-7_3","article-title":"Leptin and obesity","volume":"Vol 25","author":"Bell","year":"2006"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"18","key":"10.1016\/bs.irn.2020.03.018_bb0040","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1080\/15384101.2019.1644765","article-title":"The mystery of the ketogenic diet: Benevolent pseudo-diabetes","volume":"18","author":"Blagosklonny","year":"2019","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.018_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes & Metabolism"},{"issue":"12","key":"10.1016\/bs.irn.2020.03.018_bb0050","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1042\/BCJ20160822","article-title":"Amino acid homeostasis and signalling in mammalian cells and organisms","volume":"474","author":"Br\u00f6er","year":"2017","journal-title":"Biochemistry Journal"},{"key":"10.1016\/bs.irn.2020.03.018_bb0055","first-page":"A10643","article-title":"A randomised controlled trial of dapagliflozin on left ventricular hypertrophy in patients with type two diabetes. The DAPA-LVH Trial11","volume":"140","author":"Brown","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro-Oncology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0065","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/NDT.S75717","article-title":"Activation of mTOR: A culprit of Alzheimer's disease?","volume":"11","author":"Cai","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin use associated with reduced risk of dementia in patients with diabetes: A systematic review and meta-analysis","volume":"65","author":"Campbell","year":"2018","journal-title":"Alzheimer Disease"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0075","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3892\/ijmm.2013.1453","article-title":"Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice","volume":"32","author":"Chen","year":"2013","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/bs.irn.2020.03.018_bb0080","first-page":"241","article-title":"AMPK activation: A therapeutic target for type 2 diabetes?","volume":"7","author":"Coughlan","year":"2014","journal-title":"Diabetes, Metabolic Syndrome and Obesity"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.018_bb0085","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with T2D","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.irn.2020.03.018_bb0090","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1524-6175.2007.06694.x","article-title":"Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension","volume":"9","author":"de Rivas","year":"2007","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/bs.irn.2020.03.018_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14814\/phy2.13733","article-title":"mTORc1 activity is necessary and sufficient for phosphorylation of eNOS","volume":"6","author":"Decker","year":"2018","journal-title":"Physiological Reports"},{"key":"10.1016\/bs.irn.2020.03.018_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00421-004-1255-6","article-title":"Regulation of mTOR by amino acids and resistance exercise in skeletal muscle","volume":"94","author":"Deldicque","year":"2005","journal-title":"European Journal of Applied Physiology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and AD: A meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2019","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2018.05.023","article-title":"Newfound effect of N-acetylaspartate in preventing and reversing aggregation of amyloid-beta in vitro","volume":"117","author":"Dollet","year":"2018","journal-title":"Neurobiology of Disease"},{"issue":"9493","key":"10.1016\/bs.irn.2020.03.018_bb0115","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.018_bb0120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease","volume":"54","author":"Edwards","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0125","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/bs.irn.2020.03.018_bb0130","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.018_bb0135","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with T2D","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.irn.2020.03.018_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mcn.2019.06.009","article-title":"Mitochondrial dynamics and transport in AD","volume":"98","author":"Flannery","year":"2019","journal-title":"Molecular and Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.018_bb0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cotox.2018.05.002","article-title":"mTOR\/AMPK signaling in the brain: Cell metabolism, proteostasis and survival","volume":"8","author":"Garza-Lomb\u00f3","year":"2018","journal-title":"Current Opinion in Toxicology"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0160","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver. Role of diponectin","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.018_bb0165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbrc.2010.11.127","article-title":"Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans","volume":"404","author":"Gauthier","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.irn.2020.03.018_bb0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In AD, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.018_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/2048004019843047","article-title":"Endothelial dysfunction and heart failure: A review of the existing bibliography with emphasis on flow mediated dilation","volume":"8","author":"Giannitsi","year":"2019","journal-title":"JRSM Cardiovascular Disease"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate AD: Results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.018_bb0185","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with T2D","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/bs.irn.2020.03.018_bb0190","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fendo.2018.00621","article-title":"mTORC1 overactivation as a key aging factor in the progression to T2D mellitus","volume":"9","author":"Guill\u00e9n","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0195","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cmet.2013.02.017","article-title":"Hypothalamic mTORC1 signaling controls sympathetic nerve activity and arterial pressure and mediates leptin effects","volume":"17","author":"Harlan","year":"2013","journal-title":"Cell Metabolism"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0205","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jcmm.13432","article-title":"Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation","volume":"22","author":"Hou","year":"2018","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.018_bb0210","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/bs.irn.2020.03.018_bb0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.13938","article-title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?","volume":"22","author":"Inzucchi","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/bs.irn.2020.03.018_bb0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","article-title":"Asymptomatic hyperuricaemia: A silent activator of the innate immune system","volume":"16","author":"Joosten","year":"2019","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0225","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/bs.irn.2020.03.018_bb0230","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for AD: An appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0240","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","author":"Laffel","year":"1999","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/bs.irn.2020.03.018_bb0250","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nbd.2018.05.015","article-title":"Lysosome trafficking and signaling in health and neurodegenerative diseases","volume":"122","author":"Lei","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2020.03.018_bb0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/acel.12524","article-title":"Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways","volume":"16","author":"Lesniewski","year":"2017","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0260","first-page":"e00355","article-title":"Spironolactone promotes autophagy via inhibiting PI3K\/AKT\/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress","volume":"36","author":"Li","year":"2016","journal-title":"Biology of Reproduction"},{"key":"10.1016\/bs.irn.2020.03.018_bb0265","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/dom.13541","article-title":"Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Liakos","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.018_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/cells8010061","article-title":"Autophagy in chronic kidney diseases","volume":"8","author":"Lin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2020.03.018_bb0275","first-page":"1","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"36","key":"10.1016\/bs.irn.2020.03.018_bb0280","doi-asserted-by":"crossref","first-page":"12230","DOI":"10.1523\/JNEUROSCI.1694-14.2014","article-title":"Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid \u03b2","volume":"34","author":"Ma","year":"2014","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.018_bb0285","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/1567205015666180223093020","article-title":"Oxidative stress and decreased mitochondrial superoxide dismutase 2 and peroxiredoxins 1 and 4 based mechanism of concurrent activation of AMPK and mTOR in Alzheimer's disease","volume":"15","author":"Majd","year":"2018","journal-title":"Current Alzheimer Research"},{"issue":"7","key":"10.1016\/bs.irn.2020.03.018_bb0290","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/ijms19072043","article-title":"Role of mTOR in glucose and lipid metabolism","volume":"19","author":"Mao","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2020.03.018_bb0300","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with HF and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.018_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","article-title":"N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology","volume":"81","author":"Moffett","year":"2007","journal-title":"Progress in Neurobiology"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0310","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40336-013-0026-y","article-title":"Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physicological considerations for PET studies","volume":"1","author":"Mosconi","year":"2013","journal-title":"Clinical and Translational Imaging."},{"key":"10.1016\/bs.irn.2020.03.018_bb0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/dia.2013.0167","article-title":"Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin","volume":"16","author":"Mudaliar","year":"2014","journal-title":"Diabetes Technology and Therapeutics"},{"key":"10.1016\/bs.irn.2020.03.018_bb0325","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3389\/fnins.2018.01017","article-title":"Tau and mTOR: The hotspots for multifarious diseases in Alzheimer's development","volume":"12","author":"Mueed","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.018_bb0330","first-page":"1","article-title":"A metabolomics based pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes","author":"Mulder","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"7","key":"10.1016\/bs.irn.2020.03.018_bb0335","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in T2D","volume":"377","author":"Neal","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.irn.2020.03.018_bb0340","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1096\/fj.201700359","article-title":"Amyloid precursor protein and endosomal-lysosomal dysfunction in AD: Inseparable partners in a multifactorial disease","volume":"31","author":"Nixon","year":"2017","journal-title":"The FASEB Journal"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0345","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00023-18","article-title":"AMPK inhibits ULK1-dependent autophagosome formation and lysosomal acidification via distinct mechanisms","volume":"38","author":"Nwadike","year":"2018","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0350","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13054-015-1017-3","article-title":"Loop diuretics in acute heart failure: Beyond the decongestive relief for the kidney","volume":"19","author":"Palazzuoli","year":"2015","journal-title":"Critical Care"},{"key":"10.1016\/bs.irn.2020.03.018_bb0355","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of AD","volume":"2016","author":"Panza","year":"2016","journal-title":"BioMed Research International"},{"issue":"14","key":"10.1016\/bs.irn.2020.03.018_bb0360","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2020.03.018_bb0365","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe HF","volume":"341","author":"Pitt","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2020.03.018_bb0370","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41586-019-0895-y","article-title":"PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress","volume":"566","author":"Ranek","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.018_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010662","article-title":"Mechanistic target of rapamycin complex 1 signaling modulates vascular endothelial function through reactive oxygen species","volume":"8","author":"Reho","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.018_bb0380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for HF: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"Journal of Cardiology"},{"issue":"Pt. 9","key":"10.1016\/bs.irn.2020.03.018_bb0385","first-page":"2095","article-title":"The axonal transport of mitochondria","volume":"125","author":"Saxton","year":"2012","journal-title":"Journal of Cell Science"},{"issue":"8","key":"10.1016\/bs.irn.2020.03.018_bb0390","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Current Cardiology Reports"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.018_bb0395","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","article-title":"New insights into the role of mTOR signaling in the cardiovascular system","volume":"122","author":"Sciarretta","year":"2018","journal-title":"Circulation Research"},{"key":"10.1016\/bs.irn.2020.03.018_bb0400","doi-asserted-by":"crossref","first-page":"2764831","DOI":"10.1155\/2018\/2764831","article-title":"Possible clues for brain energy translation via endolysosomal trafficking of APP-CTFs in Alzheimer's disease","volume":"2018","author":"Sivanesan","year":"2018","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.018_bb0405","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with T2D","volume":"12","author":"Sjostrom","year":"2015","journal-title":"Diabetes and Vascular Disease Research"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.018_bb0410","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and mitochondrial cascades in AD","volume":"62","author":"Swerdlow","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1016\/bs.irn.2020.03.018_bb0415","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","article-title":"The AD mitochondrial cascade hypothesis: Progress and perspectives","volume":"1842","author":"Swerdlow","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Molecular Basis of Disease"},{"key":"10.1016\/bs.irn.2020.03.018_bb0420","series-title":"Takeda and Zinfandel pharmaceuticals discontinue TOMMORROW trial following planned futility analysis","author":"Takeda Press Release","year":"2018"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.018_bb0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt.13.73","article-title":"Brain insulin resistance in AD and its potential treatment with GLP-1 analogs","volume":"4","author":"Talbot","year":"2014","journal-title":"Neurodegenerative Disease Management"},{"issue":"8","key":"10.1016\/bs.irn.2020.03.018_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/nu10080975","article-title":"Uric acid and cognitive function in older individuals","volume":"10","author":"Tana","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/bs.irn.2020.03.018_bb0435","doi-asserted-by":"crossref","first-page":"e50069","DOI":"10.7554\/eLife.50069","article-title":"Metabolic stress is a primary pathogenic event in transgenic Caenorhabditis elegans expressing pan-neuronal human amyloid beta","volume":"8","author":"Teo","year":"2019","journal-title":"eLife"},{"key":"10.1016\/bs.irn.2020.03.018_bb0440","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npg.2008.02.004","article-title":"Don\u00e9p\u00e9zil (Aricept \u00ae)","volume":"8","author":"Trivalle","year":"2008","journal-title":"NPG Neurologie\u2014Psychiatrie\u2014G\u00e9riatrie"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0445","doi-asserted-by":"crossref","first-page":"H693","DOI":"10.1152\/ajpheart.00570.2017","article-title":"Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment","volume":"314","author":"Van Skike","year":"2018","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0450","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fphys.2018.00169","article-title":"Impact of nitric oxide bioavailability on the progressive cerebral and peripheral circulatory impairments during aging and Alzheimer's disease","volume":"9","author":"Venturelli","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0455","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.018_bb0460","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"2 Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case\u2013control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0465","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2020.03.018_bb0470","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/ncomms9048","article-title":"Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A","volume":"6","author":"Wong","year":"2015","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.018_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review","volume":"256","author":"Wulffel\u00e9","year":"2004","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.018_bb0480","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1530\/JOE-16-0160","article-title":"Obesity, hypertension and aldosterone: Is leptin the link?","volume":"230","author":"Xie","year":"2016","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/bs.irn.2020.03.018_bb0485","doi-asserted-by":"crossref","first-page":"943614","DOI":"10.1155\/2008\/943614","article-title":"Renal and vascular mechanisms of thiazolidinedione-induced fluid retention","volume":"2008","author":"Yang","year":"2008","journal-title":"PPAR Research"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.018_bb0490","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","article-title":"Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study","volume":"81","author":"Yasar","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.018_bb0495","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1042\/EBC20170021","article-title":"The mammalian ULK1 complex and autophagy initiation","volume":"61","author":"Zachari","year":"2017","journal-title":"Essays in Biochemistry"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.018_bb0500","doi-asserted-by":"crossref","first-page":"P521","DOI":"10.1016\/j.cmet.2016.09.003","article-title":"Metformin activates AMPK through the lysosomal pathway","volume":"24","author":"Zhang","year":"2016","journal-title":"Cell Metabolism"},{"issue":"22","key":"10.1016\/bs.irn.2020.03.018_bb0505","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in T2D","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["International Review of Neurobiology","Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:13:59Z","timestamp":1758748439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774220300490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128231210"],"references-count":99,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2020.03.018","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}